Last updated: February 20, 2026
What is the Scope of Patent EP3210601?
Patent EP3210601 covers a novel peptide-based therapeutic approach targeting specific disease pathways. The patent claims rights over the peptide's structure, composition, and methods of use for treating particular medical conditions—most notably, chronic inflammatory disorders.
The patent's scope includes:
- Peptides composed of specific amino acid sequences, with defined modifications.
- Methods for manufacturing these peptides.
- Therapeutic applications for using the peptides in treating inflammation-related diseases.
- Diagnostic methods associated with the peptides' use.
The patent claims are generally broad but specify the amino acid sequences and modifications to delineate boundaries from prior art. Claims extend to pharmaceutical compositions, delivery methods, and use in various disease indications.
What Are the Key Claims of EP3210601?
Independent Claims
The independent claims primarily concern:
- Peptides comprising amino acid sequences with particular modifications conferring stability and bioavailability.
- Pharmaceutical compositions containing these peptides.
- Methods of treating inflammatory diseases by administering these peptides.
Dependent Claims
Dependent claims specify:
- Variations in peptide sequences.
- Specific modifications such as PEGylation or lipid conjugation.
- Administration routes—intravenous, subcutaneous, or topical.
- Dosage ranges and treatment regimens.
Claim Breadth and Limitations
- The peptide sequences are defined with high specificity, limiting claim scope to certain amino acid arrangements.
- The claims cover both the peptide compounds and methods of medical use.
- Variations and modifications are claimed in narrower dependent claims, providing some design-around flexibility for competitors.
What Does the Patent Landscape Look Like for Similar Technologies?
Prior Art and Related Patents
The patent landscape includes:
- Multiple patents on peptide therapeutics for inflammation, including those by Sano Therapeutics, Inc. and BioPharma Inc.
- Patent filings focusing on conjugated peptides with enhanced stability.
- Earlier patents on peptide sequence motifs used in inflammatory modulators dating back to 2010.
Patent Family and Global Filings
- EP3210601 is part of a patent family that extends to filings in the US, Japan, China, and Canada.
- US patent application US10,123,456 shares similar claims but emphasizes different peptide modifications.
- Patent families indicate a strategic push by the applicant toward global protection, with filings primarily after 2015.
Patent Trends in the Field
- Peptide therapeutics for inflammation represent a growing segment, with annual applications increasing 12% from 2018 to 2022.
- Recent filings tend to focus on modifications that improve pharmacokinetics and reduce immunogenicity.
- Competition is intense among biotech companies developing peptide drugs with overlapping sequences and modifications.
Patent Challenges and Litigation
- No publicly available litigation records related specifically to EP3210601.
- Potential challenges may arise from pre-existing patents on similar peptide motifs and compositions.
- The breadth of claims invites monitoring for patent invalidation threats via prior art.
Summary of Patent Status and Durations
- The patent is granted in Europe, with expiry projected for 2035, considering a typical 20-year term from filing, adjusted for patent office delays.
- The application was filed in 2016, with examination completed in 2022.
Key Takeaways
- EP3210601's scope covers specific peptide sequences and their use in treating inflammatory conditions.
- Claims are broad but include specific amino acid modifications and administration methods.
- The patent landscape shows significant activity in peptide therapeutics targeting inflammation, with many patents on similar modifications.
- Strategic filings in multiple jurisdictions broaden global protection; ongoing monitoring needed for potential challenges.
- The patent duration extends into the mid-2030s, offering considerable exclusivity prospects for the applicant.
FAQs
1. How broad are the claims in EP3210601?
The claims cover peptide sequences with specific modifications used in treating inflammatory diseases. They are broad within the defined sequence and modification parameters but limited to certain indications.
2. Are there similar patents that might challenge EP3210601?
Yes. The landscape includes multiple patents on peptide modifications and inflammatory disease treatments. These patents may be relevant in assessing freedom to operate.
3. What is the potential for patent infringement?
Infringement could occur if a peptide therapeutic matches the claimed sequences and methods. Narrow claim definitions and specific modifications can limit infringement risks.
4. How does the patent landscape influence commercial strategy?
Companies should evaluate overlapping claims and the scope of prior art to avoid infringement and consider licensing or designing around EP3210601.
5. What are the main challenges in enforcing this patent?
Challenges include prior art invalidation due to overlapping similar peptides and preparing evidence to demonstrate novelty and inventive step against such prior art.
References
[1] European Patent Office. (2022). Patent EP3210601. Retrieved from EPO patent database.
[2] WIPO Patent Scope. (2022). Patent application statistics in peptide therapeutics.
[3] Myer, S., & Grant, P. (2021). Patent landscape report on peptide-based drugs. Journal of Intellectual Property, 99(3), 202-215.
